$25.30

FREE
SHIPPING

100% MONEY
BACK GUARANTEE

ONLINE
SUPPORT 24/7

Available on backorder. No lead time available. Please request a quote.
Sku CI01543_1_G
Chem Impex
Get Bulk Quote

Product Information

Product Name
Cytosine 1-b-D-arabinofuranoside
Brand Name
Chem Impex
Product Number
01543
CAS
147-94-4
Certificate of Analysis (COA)​
COA not found

General Information

PubChem CID
6253
IUPAC Name
4-amino-1-(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-ylpyrimidin-2-one
InChI Key
UHDGCWIWMRVCDJ-CCXZUQQUSA-N
SMILES
C1=CN(C(=O)N=C1N)C@H2C@H(C@@H(C@H(O2)CO)O)O

Application

Cytosine 1-b-D-arabinofuranoside is widely utilized in research focused on:

Antiviral Research: This compound is used in the development of antiviral medications, particularly for treating viral infections like herpes simplex virus. Its ability to inhibit viral replication makes it a valuable tool for researchers.

Oncology: It plays a role in cancer research, specifically in the study of nucleoside analogs that can be used in chemotherapy. Its effectiveness in disrupting cancer cell proliferation is being explored in various studies.

Genetic Studies: Researchers utilize this compound in molecular biology to study DNA and RNA synthesis, providing insights into genetic expression and regulation. This is crucial for understanding genetic disorders and developing gene therapies.

Pharmaceutical Formulations: It is incorporated into drug formulations to enhance bioavailability and efficacy. Its unique structure allows for improved absorption in the body, making it a preferred choice in certain therapeutic applications.

Biotechnology: In the field of biotechnology, it is used in the synthesis of modified nucleotides for various applications, including the development of diagnostic tools and therapeutic agents that target specific diseases.

References Data Source From Pubchem

[Yeasts in the lung-colonization or catastrophe? : An infectious disease complication in a patient with acute myeloid leukemia]

Publication Name: Medizinische Klinik, Intensivmedizin und Notfallmedizin
Publication Date: 2026-04
DOI: 10.1007/s00063-025-01301-9

Breaking the Barrier of Brain Disease Therapeutics: Advocating Targeted Drug Delivery for Improved Neuro-Resident Interventions

Publication Name: AAPS PharmSciTech
Publication Date: 2026-03-04
DOI: 10.1208/s12249-026-03386-7

Computer-aided drug design in acute myeloid leukemia: a comprehensive review of advances, challenges, and future prospect

Publication Name: Journal of Computer-Aided Molecular Design
Publication Date: 2026-03-03
DOI: 10.1007/s10822-026-00771-z

A narrative review of mutant isocitrate dehydrogenase AML in Japan based on experience with ivosidenib in AGILE

Publication Name: International Journal of Hematology
Publication Date: 2026-03-03
DOI: 10.1007/s12185-026-04175-5

Lymphocyte subset reconstitution and clinical outcomes following haploidentical hematopoietic stem cell transplantation

Publication Name: British Journal of Cancer
Publication Date: 2026-03-02
DOI: 10.1038/s41416-026-03345-w